Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
2mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
MM-102 (also known as HMTase Inhibitor IX) is a novel and potent peptidomimetic inhibitor of MLL1 (Mixed lineage leukemia 1) with anticancer activity. It inhibits MLL1 with an IC50 of 0.4 μM in a cell-free assay. MM-102 inhibited the growth of leukemia cells harboring MLL1 fusion proteins.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
J Am Chem Soc.2013 Jan 16;135(2):669-82.
|
Molecular Formula |
C35H49F2N7O4
|
|
---|---|---|
Molecular Weight |
669.8
|
|
CAS # |
1417329-24-8
|
|
Related CAS # |
MM-102 TFA;1883545-52-5
|
|
SMILES |
O=C(C1(NC([C@@H](NC(C(NC(C(C)C)=O)(CC)CC)=O)CCCNC(N)=N)=O)CCCC1)NC(C2=CC=C(F)C=C2)C3=CC=C(F)C=C3
|
|
InChi Key |
RZKSQRIPRKWVBU-MHZLTWQESA-N
|
|
InChi Code |
InChI=1S/C35H49F2N7O4/c1-5-34(6-2,43-29(45)22(3)4)31(47)41-27(10-9-21-40-33(38)39)30(46)44-35(19-7-8-20-35)32(48)42-28(23-11-15-25(36)16-12-23)24-13-17-26(37)18-14-24/h11-18,22,27-28H,5-10,19-21H2,1-4H3,(H,41,47)(H,42,48)(H,43,45)(H,44,46)(H4,38,39,40)/t27-/m0/s1
|
|
Chemical Name |
N-[Bis(4-fluorophenyl)methyl]-1-[[(2S)-5-(diaminomethylideneamino)-2-[[2-ethyl-2-(2-methylpropanoylamino)butanoyl]amino]pentanoyl]amino]cyclopentane-1-carboxamide
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.4930 mL | 7.4649 mL | 14.9298 mL | |
5 mM | 0.2986 mL | 1.4930 mL | 2.9860 mL | |
10 mM | 0.1493 mL | 0.7465 mL | 1.4930 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01997840 | Active, not recruiting | Drug: ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone |
Multiple Myeloma | Celgene | March 1, 2014 | Phase 1 Phase 2 |
NCT02426723 | Completed | Drug: Phase 1a: CWP232291
Drug: Phase 1b: CWP232291, Lenalidomide, Dexamethasone |
Multiple Myeloma |
JW Pharmaceutical | October 19, 2015 | Phase 1 |
NCT00985959 | Completed Has Results | Drug: JNJ-26866138 0.7 mg/m2 Drug: JNJ-26866138 1.0 mg/m2 |
Multiple Myeloma |
Janssen Pharmaceutical K.K. | July 2008 | Phase 1 |